Cancer News and Research

Latest Cancer News and Research

EDAP reduces outstanding debt by $4.6 million

EDAP TMS SA, the global leader in therapeutic ultrasound, announced today that it entered into agreements with certain holders of its senior debentures and warrants to redeem part of EDAP's outstanding convertible debt and cancel some of its outstanding warrants. Pursuant to these agreements, the Company issued 1,441,743 ordinary shares in the form of American Depositary Shares in exchange for 4,558 senior debentures (equivalent to USD 4,558,000) and 986,965 warrants, reducing the current outstanding debt by USD 4.6 million to USD 10.5 million.

3 Jan 2011

Accuray named to NASDAQ Global Select Market

Accuray Incorporated, a global leader in the field of radiosurgery, announced today that it has been named to the NASDAQ Global Select Market, the premier listing tier for NASDAQ companies. The NASDAQ Global Select Market is designated for public companies that meet the highest listing standards in the world, with measures including market value, liquidity and earnings.

3 Jan 2011

FDA grants orphan drug status for Senesco's SNS01-T in treatment of multiple myeloma

Senesco Technologies, Inc., announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the company's lead drug candidate SNS01-T for treatment of multiple myeloma.

3 Jan 2011

Cyfluent Chart, Version 2.0 receives Complete EHR certification

Cyfluent, Inc. announced today that Cyfluent Chart, Version 2.0, is 2011/2012 compliant and was certified as a Complete EHR on Friday, November 12, 2010 by the Certification Commission for Health Information Technology (CCHIT®), an ONC-ATCB, in accordance with the certification criteria adopted by the Secretary of Health and Human Services. The 2011/2012 criteria support the Stage 1 meaningful use measures required to qualify eligible providers and hospitals for funding under the American Recovery and Reinvestment Act (ARRA).

3 Jan 2011

Saint John's Health System and St.Vincent Jennings parter with Indiana Health Information Exchange

Joining a network that includes 19,000 physicians and over 80 hospitals, long-term care facilities and other healthcare organizations, Saint John's Health System and St.Vincent Jennings Hospitals are now part of the Indiana Health Information Exchange (IHIE). The two hospitals are now connected through their participation in IHIE's DOCS4DOCS ® Service.

3 Jan 2011

Celera seeks FDA premarketing approval for KIF6 Genotyping Assay

Celera Corporation today announced that it has submitted a Premarket Approval Application (PMA) to the U.S. Food and Drug Administration (FDA) for its KIF6 Genotyping Assay, a new molecular In Vitro diagnostic (IVD) test designed to detect a marker for risk of coronary heart disease (CHD) independent of traditional risk factors and aid clinical evaluation when statin treatment is being considered.

3 Jan 2011

EpiCept regains compliance with continued listing requirement of Nasdaq Capital Market

EpiCept Corporation today announced that it has received notification from the Nasdaq Listing Qualifications Department that it has regained compliance with the continued listing requirement of the Nasdaq Capital Market that it maintain a minimum market value of its listed securities of at least $35 million pursuant to Listing Rule 5550(b)(2).

3 Jan 2011

Canada’s anti-smoking warnings get larger

Canada will have larger and enhanced warning labels on cigarette packs, it was revealed in a government announcement last Thursday. Health Minister Leona Aglukkaq said that these new warnings will cover three-quarters of the front and back of cigarette packs, up from one-half.

2 Jan 2011

Diamyd Medical publishes change in total number of votes and shares

As of December 30, 2010, the share capital in Diamyd Medical AB (publ.) is 14,736,117.50 SEK. The total number of votes is 4,241,311.9 and the total number of shares is 29,472,235, divided among 1,437,876 shares of series A (1 vote) and 28,034,359 shares of series B (1/10 vote).

30 Dec 2010

Race to have the first baby of the new year

"The race to have the first baby is something all hospitals share enthusiasm for, especially in large cities like Chicago, and, unfortunately, not all hospitals play fair," said Karen Deighan, MD, OB/GYN, director of OB/GYN at Gottlieb Memorial Hospital, part of Loyola University Health System.

30 Dec 2010

General anesthesia's similarities with and differences from sleep and coma

The use of general anesthesia is a routine part of surgical operations at hospitals and medical facilities around the world, but the precise biological mechanisms that underlie anesthetic drugs' effects on the brain and the body are only beginning to be understood. A review article in the December 30 New England Journal of Medicine brings together for the first time information from a range of disciplines, including neuroscience and sleep medicine, to lay the groundwork for more comprehensive investigations of processes underlying general anesthesia.

30 Dec 2010

Low levels of microbe-killing molecules improve survival rate of people with CGD

Investigators at the National Institutes of Health have observed that the survival rate of people with a rare immunodeficiency disease called chronic granulomatous disease is greatly improved when even very low levels of microbe-killing molecules are present.

30 Dec 2010

Interaction of light with circadian systems

In a new paper published this week in the Proceedings of the National Academy of Sciences, Aziz Sancar, MD, PhD, the Sarah Graham Kenan Professor of Biochemistry and Biophysics in the UNC School of Medicine, and his colleagues have taken an important step in understanding the underlying molecular signals that influence a broad array of biological processes ranging from the sleep-wake cycle to cancer growth and development.

30 Dec 2010

Enrollment commences in belinostat-Tarceva combination trial for NSCLC

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, and Topotarget A/S announced today that the first patient has been dosed in an Investigator Initiated Trial of belinostat in combination with Tarceva® for patients with Non-Small Cell Lung Cancer (NSCLC).

30 Dec 2010

Neuroscientists say that general anesthesia is a reversible coma

The brain under general anesthesia isn't "asleep" as surgery patients are often told -- it is placed into a state that is a reversible coma, according to three neuroscientists who have published an extensive review of general anesthesia, sleep and coma, in the Dec. 30 issue of The New England Journal of Medicine.

30 Dec 2010

Dosing initiated in combination Phase I study of palifosfamide with etoposide and cisplatin/carboplatin in SCLC

ZIOPHARM Oncology, Inc., announced today that the first patient has been dosed in a Phase I, single arm, dose escalation study at the Indiana University Cancer Center of intravenous (IV) palifosfamide (ZIO-201) in combination with etoposide (VP-16) and cisplatin/carboplatin (platinum) in the treatment of small cell lung cancer (SCLC) and other cancers.

29 Dec 2010

Centocor Ortho Biotech files REMICADE sBLA for ulcerative colitis in pediatric patients

Centocor Ortho Biotech Inc. announced today that it has filed a supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) requesting the approval of REMICADE® (infliximab) for the treatment of moderately to severely active ulcerative colitis (UC) in pediatric patients who have had an inadequate response to conventional therapy.

29 Dec 2010

FDA approves Endo's FORTESTA Gel for low testosterone

Endo Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has approved FORTESTA Gel for the treatment of low testosterone, or 'Low T,' also known as hypogonadism. Symptoms associated with Low T include erectile dysfunction and decreased sexual desire, fatigue and loss of energy, mood depression, regression of secondary sexual characteristics and osteoporosis.

29 Dec 2010

CEL-SCI initiates Multikine Phase III trail for head and neck cancer

CEL-SCI Corporation announced today that it has commenced its Phase III clinical trial for Multikine®, the Company's flagship immunotherapy. CEL-SCI has now completed all of the manufacturing and regulatory requirements to begin enrollment of the study.

29 Dec 2010

Free nicotine patches to help smokers quit this New Year

British smokers thinking of quitting have a reason to celebrate this New Year. Free nicotine patches are to be offered on the NHS as part of a major drive to help smokers quit. The Department of Health has announced that smokers would be given coupons for a week’s free trial of the patches in the “Quit kits”. The patches included in the kit will be either NiQuitin Clear 21mg patches or Nicotinell TTS 30 21mg/24 hour patches, Step 1.

29 Dec 2010